NCT03797196

Phase 4Interventional

Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

View on ClinicalTrials.gov ↗

Timeline

Start date: Mar 31, 2019
Primary completion: Jun 30, 2025
Completion date: Dec 31, 2026
First posted: —
Last posted: —
Enrollment: 374
Arms / groups: 2 / —
Source: AACT · ingestion pipeline

Sponsors

University of GroningenLead sponsor
University of GroningenStudy director
University of GroningenStudy chair
Utrecht UniversityCollaborator
Leiden UniversityOverall official - principal investigator
Free University of AmsterdamCollaborator
University of AmsterdamCollaborator
Katholieke Universiteit LeuvenCollaborator
Erasmus University RotterdamCollaborator
Leiden UniversityCollaborator
Radboud UniversityCollaborator
AIDS Malignancy ConsortiumOverall official - principal investigator
University of GroningenReponsible party - principal investigator
Free University of AmsterdamOverall official - principal investigator
Radboud UniversityOverall official - principal investigator
Katholieke Universiteit LeuvenOverall official - principal investigator
Erasmus University RotterdamOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.